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 1 
INTRODUCTION 
 
In recent years, there are several divisions in the classification of 
Hypertension. Recently, a new entity has been described as normal blood 
pressure during consultation and elevated values outside of it. As such 
findings often escape the attention of the physician; it has been called 
Masked Hypertension. All evidence indicates that masked hypertension 
carries a heavy weight in long term prognosis. 
Masked hypertension is defined as a normal blood pressure in the 
clinic (<140/90 mmHg), but an elevated BP out of the clinic (ambulatory 
daytime BP or home BP>135/85 mmHg). Masked Hypertension is 
associated with many adverse effects in view of end organ damage and 
cardiovascular and cerebrovascular events. Possible characteristics of 
individuals with masked hypertension are: relatively young age, male sex, 
stress or increased physical activity during the daytime, and smoking or 
drinking habits.  
Metabolic syndrome is a cluster of metabolic disorders where in 
not just a single deranged parameter is taken into account. Patients with 
just hypertension is in increased risk with morbidity and mortality 
consequences when associated with other parameters like raised Blood 
glucose , abdominal obesity , adverse lipid profile and so on. So these 
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parameters are clustered into a single entity as metabolic syndrome. 
Prevalence of metabolic syndrome in urban Indian population is  
about 32%. 
Hypertension and Diabetes Mellitus is the major burden of non 
communicable diseases in India. Due to sedentary life style people with 
phenotype fitting into metabolic syndrome is on rise. Office BP 
measurement may be normal in some of these individuals. But strong 
clinical suspicion of raised BP can be recorded with Ambulatory BP 
monitor and hence Masked hypertension can be unearthed. These 
individuals are at increased risk of increased cardio vascular and cerebro 
vascular accidents. 
Hence, in this study we try to bring out the prevalence of Masked 
hypertension in patients with metabolic syndrome in our population . 
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AIM & OBJECTIVES 
AIM:  
 Prevalence of Masked Hypertension in patients with metabolic 
Syndrome. 
OBJECTIVES : 
Detection of masked hypertension with ABPM will help us to risk 
stratify the patients with increased cardiovascular effect and hence early 
life style modification will come into effect for the benefit of the patients. 
Masked uncontrolled Hypertension will help us to modify the 
treatment modalities of patient already on anti-hypertensive medication. 
To expose the hidden risk factors associated with hypertension 
which lead to increased blood pressure.  
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REVIEW OF LITERATURE 
Masked Hypertension : 
Clinical features suggestive of Systemic or essential hypertension 
is one of the most frequent reason for adults to visit the physician’s 
office. 
In 1992, Pickering et al described a condition in which patients 
who have a normal office BP (OBP) level are hypertensive at home. It 
was initially difficult to define nomenclature for this condition .It has 
been called isolated home hypertension, isolated ambulatory 
hypertension, reverse whitecoat hypertension, Masked Hypertension 
(MH), white coat normotension, inverse white coat hypertension, and 
inverse white coat response.  
Pickering originally used the term MH for untreated persons, the 
term is also used to refer to patients with treated hypertension in later 
publications. 
The overall accepted definition of MH recommended by the 
European Society of Hypertension is a clinical condition in which a 
patient’s OBP level is <140/90 mm Hg, but ABPM or Home BP readings 
are in the hypertensive range. 
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The recently published guidelines from the European Society of 
Cardiology/European Society of Hypertension described ‘‘isolated 
ambulatory hypertension’’ or MH, the reverse phenomenon of “white 
coat hypertension,” in individuals with normal OBP levels (<140/90 mm 
Hg) who may have elevated ambulatory BP or HBP values. 
Categories of Patients in Whom Masked  
Hypertension Should Be Suspected 
Young men with job stress. 
Patients with diabetes. 
Patients with kidney disease. 
Patients with transiently elevated blood pressure. 
Patients with unfavourable health-related lifestyle (smoking, 
obesity, excess alcohol intake). 
Patients with high to normal clinic blood pressure level. 
Patients at high cardiovascular risk 
Masked hypertension 
Ambulatory BP monitoring (ABPM) and home BP (HBP) 
recordings to conventional clinic measurement for defining BP in clinical 
practice has added a new complexity to the process; the separation of 
normotension and hypertension can now be assessed independently by 
several methods, resulting in 4 potential groups of patients:  
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Category 1 :  Normotensive - office and at home  
   (true normotension or controlled hypertension) 
Category 2 :  Hypertensive - office and at home  
  (true hypertension or uncontrolled hypertension) 
Category 3 :  Hypertensive - office and normotensive - home 
(isolated office hypertension or white coat 
hypertension) 
Category 4 :  Normotensive - office and hypertensive - home 
(masked hypertension) 
The first 2 groups are apparent and easy to deal.  
The third group has been extensively studied and is generally 
accepted as being at intermediate risk for cardiovascular (CV) morbidity 
when compared with normotensive or hypertensive individuals.  
Until recently, little attention has been paid to the fourth category 
of patients (masked hypertension) 
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Pathophysiology of Masked Hypertension 
Several conventional coronary risk factors, including sex, age, and 
job strain are associated with Masked Hypertension. 
Job strain, defined as high psychological demands plus low 
decision latitude at work, causes an increase in BP and sustained 
increases in ambulatory BP even at 3-year follow-up.  
Job stress-induced MH is a subject of increasing interest – 
Job strain was associated with incident hypertension in an 8-year 
cohort study of 3200 initially normotensive employees and is a risk factor 
for hypertension, particularly in men with very demanding jobs.  
Some individuals have been reported to have higher BP readings at 
work than in the clinic. Job strain causes an increase in ambulatory BP at 
work, at home, and during sleep (ie, individuals who are clinically 
normotensive may still experience higher ambulatory BP levels at work).  
Stress-induced MH may develop into sustained hypertension as a 
result of chronic stress due to job strain.  
Other factors include 
Smoking  
Excess alcohol intake 
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Patients with MH and sustained hypertension are at equivalent risk 
for developing CV disease. Also, stress-induced hypertension may lead to 
acceleration of target organ damage. 
Identification of Patients with Masked Hypertension 
Unmasking individuals with ambulatory BP-based or HBP-based 
hypertension is a practical problem for the clinician.  
Obviously, ABPM cannot be performed in all individuals with 
normal OBP, and the use of self BP measurement may not be practical for 
some individuals.  
Yet, present evidence suggests that MH implies increased CV risk, 
and efforts should be made to identify individuals with this condition.  
Young men who are obese and sedentary and persons with 
increased BP reactions to standing will be ideal candidates for out-of-
office BP measurement or ABPM in spite of a normal OBP level. Out-of-
office BP readings should also be performed in persons with normal OBP 
and a high CV risk profile, in diabetic individuals, and in individuals with 
kidney disease and proteinuria. 
The high prevalence of MH among patients who have had elevated 
OBP at previous examinations suggests that these individuals should also 
be evaluated to rule out MH and it helps in to attempt pharmacological or 
life style intervention in cardio vascular morbidity.  
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Patients in Whom Masked Hypertension Should Be Suspected: 
Young men who are obese and sedentary 
Patients with diabetes. 
Patients with kidney disease. 
Patients with transiently elevated blood pressure. 
Patients with sedentary habits (smoking, obesity, excess alcohol intake). 
Patients with high to normal clinic blood pressure level. 
Patients at high cardiovascular risk 
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Conditions in Which Masked Hypertension Is Likely 
Elderly male who present with increased BP variability are more 
likely to have masked hypertension than sustained normotension or 
white-coat hypertension. 
Conventional office measurement of BP in an elderly hypertensive 
patient soon after a large meal may produce postprandial reduction of BP 
and a diagnosis of masked hypertension may be questionable. 
Mental stress - raise BP to hypertensive levels except at the time of 
conventional office measurements.  
Smokers and patients who consume excessive alcohol are prone to 
masked hypertension. 
Patients with poor exercise tolerance throughout the day’s 
activities, whereas they record prehypertensive BP values in the 
physician’s office when measured at rest. 
Finally, nocturnal hypertension causes MHT in the presence of 
metabolic syndrome, diabetes mellitus, chronic kidney disease, shortened 
sleep time, or obstructive sleep apnea.  
Hence, elevated night time BP and non-dipping or rising nocturnal 
BP patterns, with or without elevated daytime ABPM values, may be 
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associated with normal clinic BP values, and diagnosis of masked 
hypertension can be made. 
In summary, there is a need for 24-hour ABPM with assessment of 
both day and night time BP to diagnose masked hypertension in the many 
conditions where it might occur. 
Shortly, ABPM is an important tool in the diagnosis of MH. 
Another basic tool is Home BP measurement (HBP). 
Differences in physical activity and emotional challenges during 
the day might account for the limited reproducibility of out-of-office BP 
measurements and might explain the large discrepancy between the 2 
methods that have been observed in some individuals. But with adequate 
patient instruction, ABPM can be satisfactorily done on suspected 
individuals. 
In addition, technical differences among the devices used for 
assessing HBP and ambulatory BP might account might play a role in 
recording BP among patients. 
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Progression of Masked Hypertension 
Pre hypertensive patients are at higher probability of getting 
diagnosed with Masked Hypertension. Pickering et al, who initially came 
up with the idea, thought that masked hypertension, along with 
prehypertension, was a precursor to sustained hypertension. But, a 5-year 
Quebec population study assessed the persistence of masked hypertension 
and its progression to sustained hypertension. Patients with baseline 
masked hypertension were studied, more than half had either masked or 
sustained hypertension at 5 years, many of whom were started on 
antihypertensive treatment; one third progressed to sustained 
hypertension, one third regressed to normotension, and 1 in 5 remained in 
masked hypertension level for more than 5 years when not treated.  
One study proved delay in making the diagnosis of masked 
hypertension may account for the high prevalence of hypertensive 
cardiovascular target organ damage. Furthermore, treated patients with 
MUCH tend to have persistent target organ damage that is comparable 
with what is observed in patients with sustained hypertension. 
PREVALENCE OF MH IN ADULTS 
It is difficult to obtain definitive data on the prevalence of MH, as 
different BP thresholds have been proposed to define MH ranges. The 
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prevalence of MH in the general population could be as high as 
10%, while data obtained in several cross-sectional studies have 
demonstrated large differences, with prevalence rates from a low of 8% to 
a high of 49%. 
Two population-based studies performed in Italy and in 
Japan report prevalence rates of 9% and 13.4%, respectively.  
The results from the Pressione Arteriose Monitorate E Loro 
Associazioni (PAMELA) study of 3200 Italians showed that 9% of the 
study population had MH, with an average OBP of 129/84 mm Hg, which 
although still within the normal range was higher than found in the true 
normotensive participants (112/77 mm Hg). The PAMELA study used a 
lower upper limit of normal for the 24-hour BP (125/79 mm Hg) 
compared with most other studies. Hence, could be argued that if a higher 
BP level had been used as the diagnostic criterion the number of 
participants with MH would have been smaller. Data from the Ohasama 
study, conducted in a small Japanese town, reported that 10.2% of 
participants with normal OBP levels had ambulatory pressures that were 
in the borderline hypertensive range (>133/78 mm Hg for 24-hour 
average) and another 3.2% in the definitely hypertensive range (24-hour 
BP >144/85 mm Hg). 
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Stergiou and colleagues investigated the level of agreement between 
ambulatory BP and HBP in the diagnosis of MH in 438 patients referred 
to an outpatient hypertension clinic. Similar proportions of patients with 
MH were diagnosed by ambulatory BP (14.2%) and HBP (11.9%).  
Among 132 participants with normal OBP levels, there was 
disagreement in the diagnosis of MH between the ambulatory BP and the 
HBP method in 23% of patients for systolic BP and 30% for diastolic BP. 
A study from Spain involving 1400 individuals older than 18 years, 
randomized and stratified by age and sex, to determine the prevalence of 
MH in the general population by means of HBP measurement. Two BP 
measurements in the office and 12 HBP measurements in 1 week were 
performed. Pressure was seen as normal when mean OBP levels were 
<140/90 mm Hg and HBP level was <135/85 mm Hg. Hypertension was 
defined as an OBP level >140 mm Hg and an HBP level >135/85 mm Hg 
or if the patient was in treatment for hypertension. MH was diagnosed 
when the OBP level was <140/90 mm Hg and home BP levels were 
>135/85 mm Hg. A total of 1153 participants (560 men and 593 women) 
were included. The prevalence of MH was 8.9% in the general population 
and 9.8% in individuals with hypertension. Other researchers found that 
36 of 267 men (13.5%) in the Cornell Worksite study had MH, defined as 
a daytime ambulatory diastolic BP level >85 mm Hg and an OBP level 
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<85 mm Hg. In a study of 319 clinically normotensive volunteers, all of 
whom had 5 clinic and 12 hour daytime ambulatory BP measurements, 
found that 23% had MH. 
The problem with patients who have treated hypertension is 
different. Screening is not an issue as these are patients in whom a 
diagnosis of hypertension has already been made. MH is of potential 
importance in these patients, however, because the OBP reading may give 
a false impression that BP is adequately controlled. The prevalence of 
MH in treated elderly hypertensive persons was 9.4% when assessed with 
HBP monitoring in the Self Measurement of Blood Pressure at Home in 
the Elderly: Assessment and Follow-Up (SHEAF) study and 19% in the 
Japan Home vs Office Measurement Evaluation (J-HOME) study.  
The J-HOME study population consisted of 3303 outpatients with 
essential hypertension who were receiving antihypertensive treatment. 
Pierdomenico and colleagues reported that one-third of patients 
whose BP was controlled by clinic criteria (OBP <140/90 mm Hg) had 
MH (daytime BP <135/85 mm Hg). 
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Prevalence of MH 
STUDY 
NO. 
OF PATIENTS 
% OF PATIENTS  
WITH MH 
Sega et al 3200 9.0 
Imai et al 1332 13.4 
Stergiou et al 438 14.2 
Marquez 
Contreras et al 
1400 8.9 
Belkic et al 267 13.5 
Selenta et al 319 23.0 
  
Masked hypertension as a marker of Cardio vascular incidents 
Data from the PAMELA study showed hazard ratio for CV death 
with a progressive increase in those with selective OBP elevations (white 
coat hypertension), selective 24-hour BP elevations (masked 
hypertension), and elevations in both OBP and 24-hour BP.  
This was also true when the above conditions were identified by 
OBP compared with HBP and ABPM values.  
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Isolated elevation in HBP compared with ambulatory BP or vice versa 
was also associated with an increased risk. There was a progressive 
increase in both CV and all-cause mortality risk in patients in whom 
OBP, HBP, and ambulatory BP were all normal over those in whom 1, 2, 
or all 3 BP measurements were elevated, regardless of which BP 
assessment was considered.  
The trends remained significant after adjustment for age and sex, in 
most instances even after further adjustment for other CV risk factors. 
Thus, white coat hypertension and MH, both when identified by OBP and 
ambulatory BP or by OBP and HBP, are significant regardless of the way 
of measurement. 
In Ohasama study, Cardio vascular outcomes in Masked 
hypertension was also examined in the, which obtained 24-hour 
ambulatory BP and casual BP values in 1332 participants (872 women, 
460 men) aged 40 years or older.  
Patients’s survival and stroke morbidity were evaluated over a 
mean duration of 10 years. Composite risk of CV mortality and stroke 
morbidity was no different from risk in patients with sustained normal BP 
(casual BP <140/90 mm Hg, daytime BP <135/85 mm Hg). 
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Study showed risk was significantly higher in participants with MH 
or sustained hypertension than in participants with sustained normal BP. 
Similar findings were observed for CV mortality and stroke morbidity 
among subgroups by sex, use of antihypertensive medication, and risk 
factor level (all P values for heterogeneity >.2). 
 Study from Italy showed 340 patients with responder hypertension 
(OBP <140/90 mm Hg and daytime BP <135/85 mm Hg), 126 with MH 
(OBP <140/90 mm Hg and daytime BP >135/85 mm Hg), 146 with false 
resistant hypertension (OBP ≥140/90 mm Hg and daytime BP  <135/85 
mm Hg), and 130 with true resistant hypertension (OBP ≥140/90 mm Hg 
and daytime BP >135/85 mm Hg).  
The follow-up period for around 5 years, the event rates per 100 
patient-years were 0.87, 2.42, 1.20, and 4.10 in patients with responder, 
masked, false resistant, and true resistant hypertension, respectively. 
After adjustment for several covariates, including OBP , Cox regression 
analysis showed that CV risk was significantly higher in patients with 
MH and in true resistant hypertension, whereas there was no significant 
difference between false resistant and responder hypertension. 
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MH IN DIABETES AND KIDNEY DISEASE 
Prevalence of treated or untreated MH in patients with diabetes and 
nephropathy remains high and hence MH is associated with a higher risk 
of end-stage renal disease in patients with chronic kidney disease. 
The prevalence and clinical significance of MH in diabetic patients 
is not known exactly.  
A study evaluated the impact of MH on microvascular 
complications and 2D echo changes in 135 normotensive type 2 diabetes 
mellitus (DM) patients. 
Patients were assessed in terms of urinary albumin excretion rate 
(UAER) measurement, echocardiography, and 24-hour ABPM. Patients 
with increased daytime BP levels (≥135/85 mm Hg) were classified as 
having MH.  
The prevalence of MH was 30% (n=41). There was no difference 
between normotensive patients and those with MH based on ABPM, in 
terms of age, DM duration, smoking status, body mass index, waist 
circumference, serum creatinine level, or glycemic or lipid profiles. The 
systolic OBP was higher in the MH group than in the normotensive 
group. UAER was also increased in the MH group, as was 
interventricular septum and posterior wall thickness. 
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  After adjustments for DM duration, sex, smoking status, and low-
density lipoprotein cholesterol and hemoglobin A1c values, all 
associations were sustained for daytime systolic BP, but not for systolic 
OBP. 
Also, the association of MH with microvascular and macrovascular 
end organ damage has been studied in 81 clinically normotensive 
Japanese diabetic persons. The prevalences of silent cerebral infarcts, 
increased left ventricular mass, and albuminuria were also evaluated. Of 
81 patients, 38 (46.9%) were classified as having MH and showed 
significantly more silent cerebral infarcts and more albuminuria, but no 
increase in left ventricular mass index, over the normotensive persons in 
the OBP monitoring and ABPM groups.  
The prevalence of MH in this diabetic population was high (47%). 
Diabetic patients with MH showed evidence of brain and kidney damage. 
Hence, out-of-office monitoring of BP may be indicated in diabetics 
whose BP is normal in the clinic. 
Metabolic Syndrome 
The metabolic syndrome (MetS) is characterized by high clinic 
blood pressure (BP), abdominal obesity, impaired fasting glucose, low 
high-density lipoprotein (HDL) cholesterol, and high triglycerides. 
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Masked hypertension (MHT), defined as having hypertension based on 
out-of- clinic BP measurements without hypertension based on clinic BP 
measurements, is associated with an increased risk for end organ damage 
and CVD events. 
Several components of the MetS have been associated with a 
higher out of clinic BP versus clinic BP.  
However, there are few data on the association between MetS and 
MHT. If the prevalence of MHT is higher among individuals with vs 
those without MetS, this may indicate a role for MetS to guide the 
indication of ambulatory BP monitoring (ABPM) for diagnosing MHT. 
MetS was defined using the 2009 harmonized definition from the 
International Diabetes Federation; the National Heart, Lung, and Blood 
Institute; the American Heart Association; the World Heart Federation; 
the International Atherosclerosis Society; and the International 
Association for the Study of Obesity.1 Specifically, MetS was defined by 
having three or more of the following components: 
1. Systolic BP 130 to 139 mm Hg or diastolic BP 85 to 89 mm Hg 
during the clinic visit, or self-reported use of antihypertensive 
medication. 
 22 
2.  Abdominal obesity, defined as a waist circumference ≥88 cm 
among women and ≥102 cm among men. 
3. Impaired glucose, defined by a fasting serum glucose ≥100 mg/dL 
or diabetes. 
4. Low HDL cholesterol, defined as <50 mg/dL among women and 
 <40 mg/dL among men. 
5. High triglycerides, defined as ≥150 mg/dL. 
Insulin resistance, obesity, atherogenic dyslipidemia and 
hypertension are associated with metabolic syndrome. These parameters 
arise due to common interlinked pathological process. Controversies arise 
due to involvement of many parameters and hence detailed evaluation is 
needed. Patients are at similar pathology to develop cardiovascular and 
Type 2 Diabetes mellitus.  
Pathophysiology and development of metabolic syndrome is a 
common entity in both the development of systemic hypertension and 
T2DM. 
Definition for the metabolic syndrome should be framed and it 
helps us to frame a diagnostic criteria in patients and help us to frame 
treatment protocols. 
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Risks involved in development of atherosclerotic cardiovascular 
disease (CVD) are known for a long term. 
Smoking, alcohol intake, high saturated fat intake, fried foods and 
other nonmodifiable risk factors are responsible for cardiovascular 
morbidity. Non modifiable ones like age increases the risk of CVD, as 
does male gender. Important to note that females on post-menopausal 
hormonal status due to loss of protective hormonal imbalance are at 
increased risk of CVD. 
Some factors like genetics are non modifiable whereas others like 
cigarette smoking comes under modifiable risk factors. The development 
of CVD can be decreased by addressing the individual risk factors, both 
by lifestyle modifications and pharmacologic treatment. 
Pooling of risk factors happen in some individuals and hence we 
can combat those factors with multi disciplinary approach. Among the 
approaches, proven and effective to start with are life style modification 
and weight reduction to appropriate levels tend to reduce the incidence 
and progression.  
This decrease in the harmful parameters with simple modification 
of life style and other approaches shoe that they have a common 
underlying causes, mechanisms and features. 
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It is important to know that metabolic syndrome involves impaired 
glucose tolerance, obesity and raise in BP on occasions not specified. 
This warrants the need to find out single causal relationship .Patients at 
high risk .of developing atherosclerotic. CVD and type 2 diabetes can be 
identified at earliest. Pathophysiology involved in the development of 
Cardio vascular risk factors can be identified. Finally it facilitates 
epidemiological and clinical studies of pharmacological, lifestyle and 
preventive treatment approaches. 
Metabolic Syndrome: 
In 1998, WHO first developed the definition of Metabolic 
Syndrome. Insulin resistance is the central cause for metabolic syndrome 
and hence it was made the absolute criteria for metabolic syndrome. 
Impaired fasting glucose which is supposed to be fasting blood sugars 
more .than 100 mg/dl and alternatively we can define by saying impaired 
glucose .values more than 140 mg/dl, for 2 hours after ingestion of 75 
.grams of glucose load.  
Homeostatic model for assessment of insulin resistance which is a 
product of fasting insulin and fasting sugar values help in assessing the 
insulin resistance in a more theoretical way.  
 25 
Invasive procedures like euglycemic hyperinsulinemic clamp 
studies which quantitatively assess the level of insulin resistance is a 
more tedious and not helpful in epidemiological assays.  
Other additional criteria are obesity, dyslipidemia, hypertension 
and microalbuminuria. 
The WHO bought together the key components of insulin 
resistance, obesity, dyslipidemia and hypertension. The definition 
requires that insulin resistance be present without it, even if all the other 
criteria were met, the patient would not have metabolic syndrome. The 
WHO definition makes patients with T2DM to be diagnosed with 
metabolic syndrome if they meet the other criteria. 
Clinical use of euglycemic. clamp studies is not .easily applied and 
does not help in large epidemiologic studies, where patient has to be 
counselled at the time of reach to physician and hence it may prove not to 
be effective at times. 
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Insulin resistance is made central to the. pathophysiology of the 
metabolic syndrome in The European Group for .the Study of Insulin 
Resistance (EGIR) like the WHO definition.  
Here, insulin resistance is defined by a .fasting plasma insulin value 
that was more than the .75th percentile. Insulin levels are measured and 
increased levels are associated with development of metabolic syndrome. 
But increased levels are not associated with insulin resistance. Hence it 
alone cannot help in diagnosing the metabolic syndrome. The other two 
additional criteria are selected from obesity, hypertension and 
dyslipidemia. The obesity criteria was simplified to waist circumference, 
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but WHO definition used a choice of waist-to-hip ratio or body-mass 
index. Microalbuminuria was eliminated as a diagnostic criterion. 
 
The National Cholesterol Education Program. (NCEP) Adult 
Treatment Panel III (ATP III) devised a .definition for the metabolic 
syndrome (National Cholesterol Education Program, 2002), further 
validated by the American Heart Association and the National Heart 
Lung and Blood Institute in 2005. Metabolic syndrome is present if three 
or more of the following five criteria is met:  
Waist circumference over 40 inches (men) or 35 inches (women)  
Blood pressure over 130/85 mmHg  
Fasting triglyceride (TG) level over 150 mg/dl 
Fasting HDL less than 40 mg/dl (men) or 50 mg/dl (women)  
Fasting blood sugar over 100 mg/dl. 
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It is the commonly used criteria of metabolic syndrome.  
It involves the key features of hyperglycemia/insulin resistance, 
visceral obesity, atherogenic dyslipidemia and hypertension. This criteria 
is very much helpful in both epidemiological and clinical assessment of 
metabolic syndrome as it is simple and easy to remember. It does not 
involve any specific criteria and only three of five criteria to be met for 
diagnosis.The definition does not involve any preconceived notion of the 
underlying cause of metabolic syndrome, whether it is insulin resistance 
or obesity. 
The International Diabetes Foundation published new criteria for 
metabolic syndrome in 2005. It requires obesity and not necessarily 
insulin resistance. The obesity requirement uses population-specific 
cutpoints depending on the population statisics. Different populations, 
ethnicities and nationalities have different distributions of norms for body 
weight and waist circumference. It also recognizes that the relationship 
between these values and the risk for T2DM or CVD differs in different 
populations. South Asian populations have an increased risk for T2DM 
and CVD at smaller waist circumferences that is not considered to meet 
the criteria in a Western population. Visceral obesity is now recognized 
as an important factor but the IDF definition has been criticized for its 
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emphasis on obesity, rather than insulin resistance, in the 
pathophysiology. 
Study was done to compare the prevalence of the metabolic 
syndrome diagnosed using three different definitions and to evaluate its 
associations with ischemic heart disease in Kaunas adult population. Data 
of preventive screening carried out in Kaunas in 2001-2002 according to 
the MONICA study protocol were used for analysis; a total of 1336 
persons aged 35-64 years (603 men and 733 women) were studied. The 
metabolic syndrome was defined by the World Health Organization, 
Adult Treatment Panel III, and International Diabetes Federation 
definitions. Ischemic heart disease was diagnosed based on the following 
criteria: a documented history of myocardial infarction, angina pectoris, 
or ischemic changes on electrocardiogram. 
The metabolic syndrome was identified for 11.3% of men and for 
9.4% of women using the World Health Organization definition, for 
19.4% of men and for 26.3% of women using the Adult Treatment Panel 
III definition, and for 30.0% of men and for 37.7% of women using the 
International Diabetes Federation definition. In male and female groups, 
the prevalence of the metabolic syndrome (irrespective of definition) 
significantly increased with age (P<0.05).  
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After adjusting for age, men diagnosed with the metabolic 
syndrome using the International Diabetes Federation definition and 
Adult Treatment Panel III definition and women diagnosed with 
metabolic syndrome using the International Diabetes Federation 
definition had a significantly higher risk of having ischemic heart disease 
as compared with those without the metabolic syndrome by the same 
definitions. The metabolic syndrome diagnosed using the World Health 
Organization definition was not associated with a significant risk of 
ischemic heart disease in men and women. In Kaunas population aged  
35-64 years, the highest prevalence of the metabolic syndrome was 
determined according to the International Diabetes Federation definition. 
International Diabetes Federation and the Adult Treatment Panel III 
definitions in establishing diagnosis of the metabolic syndrome provides 
more opportunities to identify subjects with ischemic heart disease. 
Definition of Metabolic syndrome – Remains a Paradox 
The metabolic syndrome integrates, in a single diagnosis, the 
manifestations of insulin resistance that may lead to increased 
cardiovascular morbidity and precedes type 2 diabetes. Here we discuss 
the strengths and limitations of the definitions of the metabolic syndrome 
and the epidemiology of the syndrome including information from non-
Caucasian populations. The definitions proposed by the World Health 
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Organization (WHO) and the National Cholesterol Education Program 
(NCEP) are the most frequently used. The relative risk of having long-
term complications is greater for the WHO definition; this is explained by 
the inclusion of the insulin resistance criteria. The cut-off points used in 
these definitions should be, but are not, adjusted for ethnicity; as a result, 
in non-Caucasian subjects, there is lack of agreement among these 
criteria. In a Mexican population-based survey the prevalence was 
13.61% using the WHO definition and 26.6% using the NCEP-III criteria. 
Cases identified by the WHO criteria had a more severe form of the 
disease.  
We propose that the metabolic syndrome should be viewed as a 
progressive long-term process that leads to major complications. Its 
definition should reflect the continuous nature of the disease; the 
categorical approach of the current criteria oversimplifies the complexity 
of the syndrome. The threshold for defining abnormality should be based 
on the associated risk of the identified phenotype. Refinement of the 
definition of both affected and nonaffected subjects is required. The 
available definitions include, in each of these categories, heterogeneous 
groups with a broad range of risk of future complications.  
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Risk Factors  
Risk factors for metabolic syndrome include family history, poor 
diet, and inadequate exercise. 
Metabolic syndrome is thought to be caused by adipose tissue 
dysfunction and insulin resistance. Dysfunctional adipose tissue also 
plays an important role in the pathogenesis of obesity-related insulin 
resistance. Both adipose cell enlargement and infiltration of macrophages 
into adipose tissue result in the release of proinflammatory cytokines and 
promote insulin resistance.  
Insulin resistance appears to be the primary mediator of metabolic 
syndrome. Insulin promotes glucose uptake in muscle, fat, and liver cells 
and can influence lipolysis and the production of glucose by hepatocytes. 
Additional contributors to insulin resistance include abnormalities 
in insulin secretion and insulin receptor signaling, impaired glucose 
disposal, and pro inflammatory cytokines. These abnormalities, in turn, 
may result from obesity with related increases in free fatty acid levels and 
changes in insulin distribution (insulin accumulates in fat). 
The distribution of adipose tissue appears to affect its role in 
metabolic syndrome. Fat that is visceral or intra-abdominal correlates 
with inflammation, whereas subcutaneous fat does not. There are a 
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number of potential explanations for this, including experimental 
observations that omental fat is more resistant to insulin and may result in 
a higher concentration of toxic free fatty acids in the portal circulation. 
Abdominal fat is known to produce potentially harmful levels of 
cytokines, such as tumor necrosis factor, adiponectin, leptin, resistin, and 
plasminogen activator inhibitor. 
Psychological characteristics, including anger, depression, and 
hostility, may be linked to increased risk for metabolic syndrome. 
However, psychological disorders, especially anxiety, may represent 
comorbidity or a complication of metabolic syndrome. Clearly, further 
study is warranted. 
Patients at risk of T2DM and Cardio vascular disorder 
Evaluation of metabolic syndrome help us to identify patients at 
higher risk of T2DM or CVD. But other modifiable and non modifiable 
risk factors have to be taken into account in assessing the cardio vascular 
morbidity and T2DM. 
Metabolic syndrome is less accurate to some experts in assessing 
the cardiovascular risk effects. In patients with metabolic syndrome 
Insulin resistance will play a major role and hence evaluation of other 
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parameters is questionable. This alone cannot curb the incidence of 
progression of CVD risk. 
Under the definition of metabolic syndrome which is done on 
various aspects does not include the important ones like age, gender , 
abuse like smoking, alcohol and other biochemical parameters like LDL 
are not included. But this greatly influences the Cardio vascular 
morbidity and mortality. Hence according to some this current definition 
under various categories may fall short of other risk assessment 
parameters like Framingham heart study score and hence its maximum 
potential to unmask metabolic syndrome is questionable. 
The NCEP ATP III criteria are easily applied in the clinical setting.  
The usefulness and the ease of applying this score is to get rid of 
complex parameters from the bed side point of view .It uses parameters 
where no algorithms are made use of and tedious computations are not 
involved. Parameters are mostly modifiable with patient education and 
hence it may prove to influence the strategy the patient is going to follow 
and risk stratification done on a routine basis. These parameters help the 
patient to undergo healthy life styles if they are deranged and motivate 
the patients in such a way future progression of the pathology behind this 
metabolic syndrome is curbed and healthy life is guaranteed. 
 35 
Furthermore, patient’s dependence on pharmacological medications can 
be decreased by appropriate monitoring of these parameters. 
Understanding common pathophysiological processes 
It is now known that insulin resistance, visceral adiposity, 
dyslipidemia and hypertension are interrelated in case of metabolic 
syndrome. This helps us to further unearth the factors responsible for 
these changes and come to single entity which helps us to focus on it and 
curb the occurrence and delay the progression. 
There lies a controversy in which whether metabolic syndrome is a 
single entity. Whereas people with isolated hypertension or isolated 
hyperlipidemia are at risk of CVD, but the risk is less among people who 
meet multiple criteria. Patients with isolated obesity are at risk for T2DM, 
but it is less than people with metabolic syndrome.  
Metabolic syndrome patients are at vulnerable stage of their 
pathophysiological mechanisms- hence proper guidance and in turn 
educating the patient on various aspects helps staging the patients on 
various levels and improving their biochemical profile. 
Cardio vascular effects help us to influence these factors and vice 
versa.Patients are at ease to indulge in various risk limiting exercises and 
protect themselves from further damage. 
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Epidemiological characteristics of metabolic syndrome helps 
understanding the population based statistics of risk factors and further 
asses the complex genetic influence on these parameters. 
Population in wide groups like ethinicity and race are involved in 
the pathogenicity of metabolic syndrome and its ill effects. Progression of 
metabolic syndrome can largely affected by high risk groups and hence 
stratify patients according to their race .Family history is at high 
implication in view of these risk factors.  
The features of metabolic syndrome is around the four important 
factors. 
Those features are insulin resistance , visceral obesity 
,unfavourable lipid profile and dysfunction of the endothelium .Insulin 
resistance and obesity form the crux of the issues and upon which 
metabolic syndrome components are built upon. Reducing the weight 
helps in improvement of multiple features and hence metabolic 
syndrome components. 
The further evaluation largely depends on when the patient arrives 
to clinic and the degree of damage done on regular basis is assessed and 
modification based on it is done. 
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Other factors like visceral obesity, dyslipidemia influences on a 
large a scale and these help to combat the ill effects through drugs and 
help alleviate or retard the progression of Cardio vascular ill effects . 
Modifiable things are at the primary target and they help in various 
aspects at clinic level. 
TGL, HDL levels are not that easy to control and hence these at 
pharmacologically influenced values and tight diet restrictions and other 
risk modifications help us in guiding the therapy.  
Insulin resistance 
Insulin resistance is reduced response to insulin in the body. 
Pancreas which produces insulin exerts a high secretory level and further 
causes exhaustion which leads ultimately to insulin deficiency. 
Insulin is an anabolic hormone which increases the deposition of 
substances in body and promotes growth. It removes glucose from the 
body and helps in co-ordinated use of energy. It also tries to conserve 
energy through gluconeogenesis which is done on muscles and liver. 
They serve as substrate for the energy during starvation and hence 
maintain homeostasis. 
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GLUT 4 which mediates glucose uptake through the muscles and 
adipose tissues and hence helps in regulating the downstream mechanism 
glucose metabolism. 
Various pharmacological interventions in diabetes are done at the 
level of these substrate points and hence oral anti diabetic drugs are at 
various categories. 
Physiological insulin signaling .occurs following the binding of 
insulin to the insulin receptor, a ligand-activated. tyrosine kinase. Binding 
of insulin results in tyrosine phosphorylation of downstream .substrates 
and activation of two parallel pathways which. are the phosphoinositide 3-
kinase (PI3K) pathway and the mitogen-activated protein (MAP) kinase 
pathway. Tyrosine phosphorylation of insulin receptor substrates (IRS) 
activates PI3K, leading to activation of the 3-phosphoinositide-dependent 
protein kinase 1 (PDK1) kinase and Akt kinase.  
Many of the downstream metabolic effects of insulin is due to the 
the PI3K-Akt pathway as in the vascular endothelial cells, Akt kinase 
phosphorylates and activates endothelial nitric oxide synthase (eNOS). In 
skeletal muscle and adipose tissue, Akt kinase leads to translocation of 
the insulin-responsive glucose transporter GLUT4 to the cell surface, 
leading to increased glucose uptake. 
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Activation of the MAP kinase pathway involving Ras, Raf, MAP 
kinase kinase (MEK) and extracellular regulated kinase (ERK)occurs in 
response to tyrosine phosphorylation of the Shc protein which inturn 
activates the GTP exchange factor Sos.  
The MAP kinase pathway mediates endothelin-1 (ET-1) production 
which leads to vasoconstriction through expression of the vascular cell 
adhesion molecules VCAM-1 and E-selectin, leading to more leukocyte-
endothelial interactions. This causes growth and mitogenesis effects on 
vascular smooth muscle cells. 
The PI3K-Akt pathway is affected, whereas the MAP kinase 
pathway is not affected in insulin resistance. This leads to a change in the 
balance between these two parallel pathways.PI3K-Akt pathway 
inhibition leads to a reduction in endothelial nitric oxide (NO) 
production, resulting in endothelial dysfunction, and a reduction in 
GLUT4 translocation which in turn leading to decreased skeletal muscle 
and fat glucose uptake. 
The MAP kinase pathway is unaffected and hence continuous 
production of ET-1 occurs and hence expression of vascular cell adhesion 
molecules and mitogenic stimulus to vascular smooth muscle cells. In 
these ways, insulin resistance leads to vascular abnormalities that 
predispose to atherosclerosis. 
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Insulin influences local blood flow to the tissues which further 
decides the rate of atherogenesis in majority. 
There are two separable effects through which Insulin increases 
local blood flow in tissues through the activation of eNOS. Capillary 
recruitment can occur within minutes. But the dilation of the larger-
resistance vessels increases overall perfusion between 30 minutes and 2 
hours. Both of these effects contribute to vasodilation and increased 
delivery of glucose and insulin to tissues. These vascular effects of 
insulin interfere with glucose homeostasis with blood flow and contribute 
to glucose metabolism at physiological concentrations of insulin. Further 
the pharmacologic inhibition of NO production reduces glucose disposal 
by 40%. 
Hence, insulin signaling coordinately affects peripheral glucose 
use, vascular tone and blood flow. Common mechanisms that contribute 
to insulin resistance can, therefore, also affect vascular function, 
including hyperglycemia, advanced glycation products, toxicity through 
FFAs, obesity, dyslipidemia and other proinflammatory conditions. 
Visceral adiposity 
Insulin-mediated glucose uptake is reduced in insulin resistance 
and is clearly related to insulin resistance. Crosstalk between metabolism 
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and vascular function are the mechanisms for this probable cause that 
involve adipokines, which are made by adipose tissue, that modulate.  
They are tumor necrosis factor alpha (TNF alpha ) and interleukin-
6 (IL-6), which are proinflammatory and contribute to insulin resistance 
and vascular dysfunction. The renin angiotensin system is largely 
activated in adipose tissue, leading to hypertension and insulin resistance.  
But adiponectin is a protective adipokine that couples insulin 
sensitivity with energy metabolism. In obesity, T2DM and metabolic 
syndrome adiponectin levels are decreased. In addition to these 
adipokines, FFAs, which are released from visceral fat, and bioactive 
lipid intermediates act together to impair the PI3K-Akt pathway and 
increase oxidative stress 
Intra-Abdominal Fat Is a Major Determinant of the National 
Cholesterol Education Program Adult Treatment Panel III Criteria 
for the Metabolic Syndrome: 
A large number of apparently healthy men and women of varying 
age, with differential effects of insulin sensitivity and central body fat 
distribution on the features of the metabolic syndrome as defined by 
NCEP ATP III were included. Study showed both insulin resistance and 
central adiposity are significant correlates of the metabolic syndrome. 
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Intra abdominal fat area was independently associated with all of the 
metabolic syndrome criteria, whereas insulin sensitivity was 
independently associated with the criteria for HDL cholesterol, TGs, and 
FPG. 
  This study suggests that accumulation of intra-abdominal adipose 
tissue is an important determinant of the metabolic syndrome. The 
significant relation of visceral adiposity with all the features of the 
metabolic syndrome was in part independent of the effect of insulin 
resistance and abdominal subcutaneous fat, suggesting an important role 
for visceral adiposity. Finding like visceral adiposity is significantly 
associated with the features of the metabolic syndrome is consistent with 
other studies that have examined the relation of this parameter to 
cardiovascular disease risk factors. Visceral adiposity, but not abdominal 
subcutaneous fat, is independently associated with insulin resistance , 
lower HDL cholesterol , higher apolipoprotein B and triglyceride levels, 
smaller LDL particles , aortic stiffness, coronary artery calcification , and 
higher BP. Reduction in visceral fat by weight loss or surgical removal is 
associated with increases in insulin sensitivity. 
Unfavourable Atherogenic dyslipidemia 
  High plasma TG levels, low HDL cholesterol levels and an 
increase in small dense LDL are associated with atherogenic dyslipidemia 
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wherein Insulin resistance and visceral obesity are the strong  
reasons for it. 
There are several ways in which Insulin resistance leads to 
atherogenic dyslipidemia. Insulin inhibits lipolysis in adipocytes, so 
impaired insulin signaling increases lipolysis, resulting in increased FFA 
levels.  
FFAs serve as a substrate for synthesis of TGs in the liver. FFAs 
also stabilize the production of apoB, the major lipoprotein of very-low-
density lipoprotein (VLDL) particles, resulting in more VLDL 
production. Insulin degrades apoB by PI3K-signalling pathways, so 
insulin resistance directly increases VLDL production. Finally, insulin 
regulates the activity of lipoprotein lipase, the rate-limiting and major 
mediator of VLDL clearance. 
Thus, increase in VLDL production and a decrease in VLDL 
clearance is the reason for atherogenicity in insulin resistance. This 
increase in VLDL can further aggravate the situation by getting 
metabolized to remnant lipoproteins and small dense LDL, both of which 
can induce atheroma formation. The TGs in VLDL are transferred to 
HDL by the cholesterol ester transport protein (CETP) in exchange for 
cholesteryl esters, resulting in TG-enriched HDL and cholesteryl ester-
enriched VLDL particles.  
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The hepatic lipase better degrades the TGL rich HDL particles and 
so it is cleared rapidly from the circulation, leaving fewer HDL particles 
to participate in reverse cholesterol transport from the vasculature. 
Endothelial dysfunction 
Inner surface of the blood vessels are lined by endothelium. It 
forms one of the casual factor at microscopic level that may be reflected 
phenotypically on a larger scale .Metabolic syndrome is largely due to the 
disturbance in endothelial layer integrity which is maintained largely by 
physiological protective mechanisms. Endothelial surface constantly 
produce protective mediators like Nitric oxide, Prostaglandins like 
Prostacyclins and help maintain homeostasis. In case of metabolic 
syndrome the disturbance in the endothelial layer superimposed with 
active interaction of the blood components with its layer provide a nidus 
for pathophysiology. Interaction of WBC with endothelial layer causes 
inflammation, platelet interaction may lead to thrombus and other 
hazardous long term complication.  
Unfavourable atherosclerosis is largely due to the intimal layer 
weakness and it forms the basis for other problems. Normal endothelial 
function protects against these processes. Endothelial dysfunction is 
central to the pathogenesis of atherosclerosis. 
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Endothelial dysfunction occurs when the endothelium fails to serve 
its normal physiological and protective mechanisms. This might be 
because the endothelium is damaged or missing, as in the case of denuded 
endothelium in coronary arteries that have been subjected to angioplasty. 
Oxidative stress, hyperglycemia, advanced glycation products, FFAs, 
inflammatory cytokines or adipokines are mostly responsible for the 
unfavourable response of the endothelium to these insults . A common 
entity of endothelial dysfunction was the reduced bioavailability of NO in 
the vasculature. 
Several mechanisms responsible for endothelial dysfunction are:  
The most important is formation of Super peroxide nititrite due to 
the interaction of the NO with free radicals. Asymmetric 
dimethylarginine (ADMA) will compete with arginine to reduce 
endothelial NO production. eNOS requires enzymatic cofactors, 
including flavin adenine dinucleotide (FAD), flavin mononucleotide 
(FMN), NADPH and tetrahydrobiopterin.  
In the absence of tetra hydro biopterin, electron transport through 
eNOS can become uncoupled, resulting in the generation of superoxide 
by eNOS. Superoxide, whether formed by NADPH oxidase or by 
uncoupled eNOS, reacts with NO in an extremely rapid, diffusion-limited 
reaction to form peroxynitrite anion, which has its own toxic effects. 
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eNOS phosphorylation at S1177 appears to be a crucial regulator of its 
enzymatic activity. This results in increased electron flux through the 
reductase domain and reduced calmodulin dissociation. As a result, eNOS 
becomes more active and produces more NO, even at resting levels of 
intracellular calcium.This protective eNOS phosphorylation is diminished 
in diabetes, hypercholesterolemia and atherosclerosis. Insulin signaling 
through the PI3K-Akt pathway increases eNOS phosphorylation.  
Estrogens, statins, VEGF and leptin all increase eNOS 
phosphorylation by Akt kinase. Through AMP kinase Adiponectin, the 
protective adipokine, increases eNOS phosphorylation. The fact that 
diverse signaling pathways affect multiple kinases that converge to 
modulate eNOS activity by phosphorylation suggests that this is a 
common integration point that underlies endothelial dysfunction from 
various causes. This phosphorylation of eNOS at S1177 appears to be a 
crucial step in the regulation of eNOS activity and an important target for 
intervention to treat endothelial dysfunction. 
Akt kinase activity is reduced in insulin resistance individuals and 
hence resulting in diminished eNOS phosphorylation and activity. The 
phosphorylation of eNOS at S1177 is necessary for the hemodynamic 
actions of insulin which results in diminished blood flow to skeletal 
muscle, creating a vicious cycle where endothelial dysfunction then 
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worsens insulin resistance. In addition,endothelial dysfunction is further 
due to insulin-mediated ET-1 expression and vascular smooth muscle 
mitogenic effects are not affected by insulin resistance,  
Visceral adiposity causes endothelial dysfunction through the 
effects of resistin, IL-6 and TNF alpha on eNOS phosphorylation. In 
addition to blocking IRS-1 activation, TNF alpha directly activates 
NADPH oxidase, increasing superoxide generation. TNF alpha also 
stimulates lipolysis, resulting in FFA release. Adiponectin, which 
stimulates eNOS phosphorylation, is diminished in metabolic syndrome. 
Leptin resistance also increases the generation of reactive oxygen species. 
And hence visceral fat also contributes to the endothelial dysfunction. 
This combination of diminished PI3K-Akt signalling, increased reactive 
oxygen species and increased ET-1 production leads to the FFAs to cause 
endothelial dysfunction. 
In summary, the central features of the metabolic syndrome are 
insulin resistance, visceral adiposity, atherogenic dyslipidemia and 
endothelial dysfunction. These conditions are interrelated and share 
common mediators, pathways and pathophysiological mechanisms.  
A comprehensive definition of the metabolic syndrome, expressed as 
simply as possible, would contain only these features. The requirement of 
multiple criteria would ensure the exclusion of people with individual 
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components (e.g. isolated hypertension or isolated hyperlipidemia), as 
opposed to the composite pathophysiology discussed above. Inclusion of 
both TG and HDL criteria increases the specificity for atherogenic 
dyslipidemia, and inclusion of the blood pressure criterion ensures that 
the physiologic derangements are severe enough to have resulted in 
endothelial dysfunction. 
Of the various definitions for the metabolic syndrome, the NCEP 
ATP III definition is the easiest to apply clinically and epidemiologically, 
because it uses straightforward criteria that are measured readily. Despite 
the ongoing controversy about whether the concept of metabolic 
syndrome is useful, it clearly defines specific pathophysiological 
mechanisms that link the central features. Consideration of metabolic 
syndrome as a specific entity allows for research on the genetic basis for 
susceptibility to this syndrome, a better understanding of its underlying 
pathophysiology and the development of treatment approaches. 
Further there is an entity called Anti psychotic induced metabolic 
syndrome where in Schizophrenia patients and other psychiatric patients 
treated with second generation anti psychotics especially clozapine but 
also olanzepine, risperidone and quetiapine because they induce 
substantial weight gain. 
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The mechanism of weight gain is due to drug’s affinity for 
histamine receptors and neurobiological mechanism that regulate appetite 
and metabolism through production and activity of serotonin, leptin and 
tumour necrosis factor-alpha. As a result these patients develop glucose 
intolerance. 
These patients are treated with aggressive weight reduction, 
increasing physical activity and metformin or a combination of these. 
Metformin at daily dose of 750 mg may prevent weight gain if it is 
initiated at the onset of olanzepine treatment.Conversion to aripiprazole 
also helps in this situation.  
Ambulatory Blood Pressure Monitoring (ABPM): 
Ambulatory Blood Pressure Monitoring (ABPM) is done for 
blood pressure is measurement as we move around, living our normal 
daily life. It can be measured for up to 24 hours. A small monitor is 
attached to a belt around patient’s waist and connected to a cuff around 
your upper arm. It is small enough not to affect normal daily life and can 
even sleep with it on. 
Measurement of blood pressure at regular intervals up to 24 hours 
helps us to get a clear idea on how blood pressure changes throughout the 
day.  
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As the patients are advised to carry on with normal routine, it 
avoids the problems of white coat syndrome. 
Now a day with wide patient education and easy accessibility to BP 
measurements 24 hour value comes to play .It modulates the hypertensive 
treatment and hence dosage can be adjusted accordingly. 
  Various clinical and epidemiological researches show an important 
role of ambulatory BP monitoring (ABPM) in the management of 
hypertensive patients. A 24-h BP measurement helps to determine the 
absence of nocturnal dipping status and evaluate BP control in patients on 
antihypertensive therapy. Enhanced diagnosis of masked and white coat 
hypertension is done with Ambulatory BP monitor. 
There has been a dramatic shift in the manner in which blood 
pressure (BP) is measured to provide far more comprehensive clinical 
information than that provided by a single set of office BP readings. 
Extensive clinical and epidemiological research shows an important role 
of ambulatory BP monitoring (ABPM) in the management of 
hypertensive patients. A 24-h BP profile helps to determine the absence 
of nocturnal dipping status and evaluate BP control in patients on 
antihypertensive therapy. The ability to detect white-coat or masked 
hypertension is enhanced by ambulatory BP monitoring.  
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The Center for Medicare and .Medicaid Services suggested ABPM 
for confirming for the identification of patients with white-coat 
hypertension in 2001. 
  The National Institute for Health and Clinical Excellence (NICE) 
in 2011 in the UK published guidelines that suggested the. use of ABPM 
in all patients suspected of having hypertension.  
The European Society of Hypertension (ESH) 2013 guidelines also 
suggested greater use of ABPM in clinical practice. ABPM use should be 
considered in relation to its cost, the complexity of data evaluation, as 
well as patient inconvenience but the advantages of ABPM are evident 
from a clinician point of view. 
Thresholds for Hypertension Diagnosis Based on ABPM 
24-hour Average ≥130/80 mm Hg 
Awake /daytime average ≥135/85 mm Hg 
Asleep /night-time average ≥120/70 mm Hg 
Number of Measurements for a Satisfactory ABPM 
Number of measurements was a cause of considerable question 
considering the measurement of BP values on a 24 hour basis. No 
concrete data is available to which there are recommendations for a 
satisfactory ABPM recording. Satisfactory ABPM recording should have 
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more than 70% of expected measurements as per the general 
recommendation in clinical practice. This figure will be influenced by the 
duration of daytime /awake or night time / asleep periods, and by the 
frequency of measurements selected for each period (usually at 30-minute 
but often at 15- or 20-minute intervals).  
The ESH Guidelines on Blood Pressure Measurement 
recommended 14 measurements during the day and 7 measurements at 
night based on using a fixed time method for defining day and night time 
periods with the retiring 2101–0059 hour and rising 0601–0859 hour 
periods during which BPs are subject to considerable variation being 
eliminated, leaving the daytime period extending from 0900 to 2100 hour 
and night-time from 0100 to 0600 hour. These variations are eliminated 
from the analysis that may exist between the young and the old and in 
different cultures to some extent possible so that uniformity is 
maintained.12 Having considered what evidence is available and the 
practical issues of performing repeat ABPM, in practice, the authors of 
the Position Paper saw it as being reasonable to increase the minimum of 
daytime measurements to 20 while retaining a minimum 7 measurements 
at night based on measurements being performed every 30 minutes, or 
more frequently throughout the entire 24-hour period. 
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Evaluation of ABPM Data 
Definition of daytime and night-time 
Daytime and night-time intervals are best defined using sleeping times 
reported by individual users’ diary cards (awake and asleep periods) 
Fixed narrow time intervals can be applied by discarding transition 
periods between daytime and night-time (eg, daytime defined as 0900–
2100 h and night-time 0100–0600 h) 
Editing and requirements 
Editing is not necessary for calculating average 24-h, daytime and night-
time values 
The ABPM should be repeated if the following criteria are not met 
24-h Recording with ≥70% of expected measurements 
20 Valid awake (0900–2100 h) 
7 Valid asleep (0100–0600 h) 
Blood pressure measurements at 30 min intervals throughout 24 hours 
For research purposes ≥2 valid daytime and 1 valid night -time 
measurement per h 
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The Clinical Indications for ABPM include  
Identifying white-coat hypertension phenomena 
White-coat hypertension in untreated subjects 
White-coat effect in treated or untreated subjects 
False resistant hypertension in treated subjects 
Identifying masked hypertension phenomena 
Masked hypertension in untreated subjects 
Masked uncontrolled hypertension in treated subjects 
Identifying abnormal 24-h blood pressure patterns 
Daytime hypertension 
Siesta dipping/postprandial hypotension 
Nocturnal hypertension 
Dipping status 
Morning hypertension and morning blood pressure surge 
Obstructive sleep apnoea 
Increased blood pressure variability 
Assessment of treatment 
Increased on-treatment blood pressure variability 
Assessing 24-h blood pressure control 
Identifying true resistant hypertension 
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Assessing hypertension in the elderly 
Assessing hypertension in children and adolescents 
Assessing hypertension in pregnancy 
Assessing hypertension in high-risk patients 
Identifying ambulatory hypotension 
Identifying blood pressure patterns in Parkinson disease 
Endocrine hypertension 
 
Using an ambulant Monitor: 
Fitting the monitor 
1.  Takes around 15 – 20 minutes.  
2.  Make the patient to relax in a quiet room. 
3.  Patient’s details are entered in BP monitor. 
4.  Initially measure BP readings in both the arms. 
5.  If the difference is less than 10 mm Hg use the non dominant 
arm for monitoring. 
6.  If the difference in Systolic pressure is more than 10 mm  
hg – arm with higher BP is used. 
7.  Appropriate cuff to be selected. 
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8.  Inactivate the display – Patient not to be distracted with BP 
values. 
9.  Educate patient how to remove and inactivate the monitor 
after 24 hours. 
Recommended size of cuffs for measuring blood pressure 
 Dimension 
Child or lean adult 12 cm × 18 cm 
Adult 12 cm × 26 cm 
Adult with large arm 12 cm × 40 cm 
Following Instructions are given to the patients 
1.  Explain the procedure.  
2. The frequency of inflation and deflation of the cuff. 
3. Educate how to manually deflate the cuff. 
4. Instruct in case of failed inflation, apparatus will inflate again.  
5. Instruct the patient to keep their arm steady and at heart level 
during the measurement. 
6. To involve in normal activities between the measurements. 
7. To place the monitor under a pillow while sleeping. 
So this interlinking of metabolic syndrome and masked 
hypertension is done with Ambulatory BP monitoring.  
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MATERIAL AND METHOD 
Study design : Prospective observational study 
Study period : 6 months  
Study area :  Teritiary health care centre. 
Study population 
Patients who fulfill the clinical criteria for metabolic syndrome. 
Patients with sedentary life style with pre – hypertension.  
Inclusion criteria:-  
 Patient’s age group – 18 to 65 yrs both males and females with 
written consent satisfying any of the following criteria 
• Patients with large waist line (men >102cm and female >88cm) 
• Patients with high Triglyceride levels. (>150 mg/dl) 
• Patients with low HDL levels (<50 mg/dl in females and <40 
mg/dl in males) 
• Patients with high fasting Plasma glucose- Suspected to have   
Type 2 Diabetes mellitus(>100 mg/dl ) 
• Patients with Pre hypertensive range of Blood pressure. 
      (130-139 mmhg and 85-89 mmhg ) 
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Exclusion criteria:- 
• Chronic hypertensive patient with end organ damage. 
• Patients with severe hypertension.Presenting with hypertensive 
Urgency and emergency. 
• Patients with irregular rhythms on Electrocardiography. 
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STATISTICAL ANALYSIS  
STATISTICAL ANALYSIS 
 The data was collected in the master chart obtained in the Microsoft 
excel format. 
 The collected was analysed with SPSS 16.0 version. To describe 
about the data descriptive statistics frequency analysis, percentage 
analysis were used for categorical variable and the mean were used for 
continuous variable. To find the significant of two variables by unpaired  
t test. To find the correlation between the two variables chi-square test 
were used with p value less than .05 is considered as significant. 
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RESULTS 
The results of the study conducted among 65 metabolic syndrome 
patients were presented here. The age of the study participants ranged 
from 34 to 59 years. Mean was 45 years with SD 5.6 years. Greater 
proportion was males 36 (55.4%). Greater proportions were non smokers 
42(64.6%). Greater proportion of the patients 89.2% had 
Diabetes/impaired fasting blood sugars as co morbidity. The prevalence 
of masked hypertension among metabolic syndrome patients was 
43(66.2%). 
Table-1 Profile of patients with metabolic syndrome (n=65) 
Variables  Frequency Percentage 
Gender Males 36 55.4 
Females 29 44.6 
Smoking 
history 
Smoker 23 35.4 
Non smoker 42 64.6 
Diabetes 
/Impaired FBS 
Yes 58 89.2 
No 7 10.8 
Masked 
Hypertension 
Yes 43 66.2 
No 22 33.8 
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Male
55%
Female
45%
Gender distribution
Smokers
35%
Non smokers
65%
Smokers /Non Smokers
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Yes
89%
No
11%
Diabetes/Impaired Fasting Blood Glucose
Yes
66%
No
34%
Masked Hypertension
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The variables gender, smoking habit and Diabetes are not 
significantly associated with presence of masked hypertension. 
Table 2. Association between certain  
variables and masked hypertension 
Variable 
Masked hypertension 
N (%) 
 
P value 
1. Sex   
Female 17(58.6) 0.187 
Male 26(72.2)  
2. Smoker   
Yes 18(78.3) 0.104 
No 25(59.5)  
3. Diabetes   
Yes 7(100)  
No 36(62.1) 0.085 
 
Mean age of patients with masked hypertension is significantly 
higher (47 years) than patients who do not have masked hypertension. 
(41.6 years). (p=0.000).  
Mean weight of patients with masked hypertension is significantly 
higher (72 kgs) than patients who do not have masked hypertension (64.2 
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kgs). (p=0.000). No association was found between height and masked 
hypertension. Mean BMI is significantly higher among patients with 
masked hypertension (26.2) than among patients without masked 
hypertension (23). This difference was statistically significant (p=0.000). 
Mean systolic and diastolic BP are significantly higher among patients 
with masked hypertension than among patients who do not have masked 
hypertension. (p=0.000). Patients with masked hypertension have 
significantly higher waist circumference (99.8 cms) than patients who do 
not have masked hypertension (94.5 cms). (p=0.007). No significant 
difference in fasting blood sugar levels between the two groups. HDL is 
significantly lower and TGL is higher in patients with masked 
hypertension (p<0.05). 
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Mean age of patients with masked hypertension is significantly higher  
(47 years) than patients who do not have masked hypertension. (41.6 
years). (p=0.000).  
 
47
41.6
38
39
40
41
42
43
44
45
46
47
48
Masked Hypertension No Masked hypertension
Mean age group (years) with and without Masked 
hypertension
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Mean BMI is significantly higher among patients with masked 
hypertension (26.2) than among patients without masked hypertension 
(23). This difference was statistically significant (p=0.000). 
26.2
23
21
22
23
24
25
26
27
Masked Hypertension No Masked hypertension
Mean BMI- with and without Masked 
hypertension
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Mean weight of patients with masked hypertension is significantly 
higher (72 kgs) than patients who do not have masked hypertension  
(64.2 kgs). (p=0.000). 
 
72
64.2
60
62
64
66
68
70
72
74
Masked Hypertension No Masked hypertension
Mean weight (Kg) - with and without Masked 
hypertension
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Mean systolic and diastolic BP are significantly higher among 
patients with masked hypertension than among patients who do not have 
masked hypertension. (p=0.000). 
135.4
128.2
124
126
128
130
132
134
136
Masked Hypertension No Masked hypertension
Mean Systolic BP  (mm Hg)
85.5
81
78
79
80
81
82
83
84
85
86
Masked Hypertension No Masked hypertension
Mean Diastolic BP  (mm Hg)
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Waist Circumference ( in cm ) 
 
Patients with masked hypertension have significantly higher waist 
circumference (99.8 cms) than patients who do not have masked 
hypertension (94.5 cms). (p=0.007) and hence statistically significant. 
 
No significant difference in fasting blood sugar levels between the 
two groups 
99.8
94.5
91
92
93
94
95
96
97
98
99
100
101
Masked hypertension No masked hypertension
107.3
99.5
94
96
98
100
102
104
106
108
Masked hypertension No Masked Hypertension
Fasting Blood Glucose
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HDL is significantly lower and TGL is higher in patients with 
masked hypertension (p<0.05) and was statistically significant. 
42.1
46
40
41
42
43
44
45
46
47
Masked Hypertension No Masked Hypertension
HDL
203.3
167.7
0
50
100
150
200
250
Masked Hypertension No Masked Hypertension 
TGL
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Table 3: Mean value comparison of various  
parameters and Masked hypertension 
Variable Mean P value 
Masked 
Hypertension 
present 
Masked 
Hypertension 
absent 
Age 47.1 41.6 0.000 
Weight 72.1 64.2 0.000 
Height 166.0 166.7 0.735 
BMI 26.2 23.0 0.000 
Clinic SBP 135.4 128.2 0.000 
DBP 85.5 81.0 0.000 
Waist 
circumference 
99.8 94.5 0.007 
Fasting blood 
sugar 
107.3 99.5 0.051 
HDL 42.1 46.0 0.011 
TGL 203.3 167.7 0.000 
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Table 4: Association between BMI and Masked hypertension 
BMI 
Masked 
Hypertension 
present 
Masked 
Hypertension 
absent 
Mean 26.2 23.0 
Standard deviation 2.8 2.7 
Median 26 23 
25th centile value 24 21 
75th centile value 28 24.2 
Range 21-35 19-31 
 
Mean BMI is significantly higher among patients with masked 
hypertension (26.2) than among patients without masked hypertension 
(23). This difference was statistically significant (p=0.000). 
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DISCUSSION  
Metabolic syndrome and Masked hypertension are on raise. Rise in 
one entity can be attributed to the other .India being a Diabetic Capital of 
the world and majority of the population is under the working group 
burden of Non Communicable diseases are increasing. Attributes like 
sedentary lifestyle and shift of population from rural to urban has made 
the diagnosis complex. 
Cardio vascular and Cerebro vascular morbidity and mortality is 
largely due to Type 2Diabetes mellitus and Systemic Hypertension. 
Prevention is better than cure. Hence, these two attributes Masked 
hypertension and metabolic syndrome help us aggressively intervene at 
earlier stages and hence decrease the worst outcomes. 
Western literatures have attributed prevalence of masked 
hypertension around 8 to 30 percent depending on the population it was 
studied. 
Here we approach patients with criteria fulfilling metabolic 
syndrome and assess their 24 hour Blood pressure measurement through 
Ambulatory BP monitor and unmask their hypertension which may show 
normal Clinic BP reading. 
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This explains the need for assessing the prevalence of masked 
hypertension in patients with metabolic syndrome in our population. 
Study was conducted in 65 patients who fulfil the atleast 3 out of 5 
metabolic syndrome criteria.  
The prevalence of masked hypertension among metabolic 
syndrome patients in our study is 66.2%.  
According to Colantonio et al the prevalence of masked 
hypertension among African Americans is 62.3% 
The age of the study participants ranged from 34 to 59 years. Mean 
was 45 years with SD 5.6 years. Greater proportion was males 36 
(55.4%) and females ranging 29(44.5%). 
Among the study group greater proportion were non smokers 
amounting to 64.6% .But smoking is attributed to development of 
metabolic syndrome.  
Impaired fasting Blood sugars were taken irrespective of the 
diabetic status of the patient and 89.2% of the patients who satisfy 
metabolic syndrome criteria are Diabetic. Compared with The Jackson 
Heart study done by Colantino et al. Impaired glucose component was 
around 19.2% in their study. 
Hence, this shows the high incidence of metabolic and masked 
hypertension among our population. 
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Other anthropometric details like height and weight were taken into 
account.  
Among height and weight, as expected weight has a significant 
association.  
And obviously BMI plays a major role and hence development of 
metabolic syndrome. 
Among 65 patients, the mean weight is 72.1 kg among masked 
hypertension patients compared to 64.2kg among patients with no masked 
hypertension and hence proved to be statistically significant entity. 
Likewise BMI was statistically significant with mean around 26.2 
among masked hypertensive group and hence adding to the strength of 
this study. 
Abdominal / visceral obesity is well phenotypically measured in 
terms of waist circumference and it was statistically an important 
parameter to include.  
Abdominal obesity plays a significant role with 54% constituting 
the metabolic syndrome in a study conducted by Colantonio et al. 
Hypertension is one of the major reasons for clinic visit and 
metabolic syndrome includes major inclusion criteria as a pre 
hypertensive range of Systolic and diastolic BP readings .This helps to 
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pick up significant number of patients to intervene at the earliest and to 
impart life style medication and drug treatment accordingly. 
In this study mean Systolic BP was found to be 135.4 mm hg and 
Diastolic BP to be 85.5 among masked hypertensive patients and these 
variables were statistically significant.  
Cardio vascular morbidity and mortality is linked largely to lipid 
profile and HDL and TGL levels are measured. 
Mean HDL profile was 42.1mg/dl among masked hypertension 
patients compared to mean of 46 mg/dl among patients with no masked 
hypertension. 
Likewise Triglycerides levels were higher (203.3mg/dl) among 
patients with masked hypertension than patients (167.7) without masked 
hypertension. 
In our study important parameters attributing to metabolic 
syndrome are statistically significant in terms of development of masked 
hypertension. 
Early diagnosing of masked hypertension helps us to address the 
causative modifiable risk factors in terms of metabolic syndrome and 
provide a concrete solution on a long term basis and reduce disease 
burden on the society. 
  
 78 
CONCLUSION 
Masked hypertension is present significant numbers in our 
population.  
ABPM can bridge this diagnostic gap and help us in early 
intervention. 
Traditional risk factors which may be modifiable or non modifiable 
still play a role in development of metabolic syndrome. 
Impaired fasting glucose is a major component in the early 
interpretation of metabolic syndrome and it is an important component in 
the diagnostic criteria for metabolic syndrome.  
Hence, in view of high prevalence ABPM measurement is 
warranted in high risk groups with normal clinic Blood pressure. 
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 ANNEXURES 
PROFORMA 
Name:                                                     Age/sex:                                             
Address:                                                  IP NO/OP NO: 
Kuppusamy Socio economic State: 
QUESTIONNAIRE: 
Family History of DM / hypertension : 
Do you exercise regularly : 
Diet restriction : 
Addictions : 
 
INVESTIGATIONS: 
Renal function tests: 
 
Lipid profile: 
 
Fasting Blood sugar: 
Electrocardiography: 
 
IMPAIRED FASTING GLUCOSE / T2DM – YES /NO 
METABOLIC SYNDROME CRITERIA: 
INCREASED WAIST CIRCUMFERENCE – YES /NO 
INCREASED TGL – YES/NO 
REDUCED HDL – YES/NO 
       RAISED BLOOD PRESSURE – YES /NO 
METABOLIC SYNDROME CRITERIA  FULFILLED – YES /NO 
 
Ambulatory Blood pressure report 
 Summary : 
 Min Mean Max 
        Systolic BP      
       Diastolic BP    
       Heart rate    
Day Summary : Hours –( For example – 6.00 to 22.00 hours ) 
 Min Mean Max 
        Systolic BP      
       Diastolic BP    
       Heart rate    
 
 
 
Patient name : 
  
Identification No: 
 
 
Scan Start date: 
  
Clinic SBP/DBP : 
 
 
Scan Start time: 
  
Total reading: 
 
 
Scan end Date: 
  
Successful reading: 
 
 
Scan end time: 
  
Percent successful: 
 
 Night Summary : Hours –  (For example -22.00 to 6.00 hours) 
 Min Mean Max 
        Systolic BP      
       Diastolic BP    
       Heart rate    
 
Awake Summary : Hours –  (For example -7.00 to 1.30 hours) 
 Min Mean Max 
        Systolic BP      
       Diastolic BP    
       Heart rate    
 
Asleep Summary : Hours –  (For example -1.30 to 7.00 hours) 
 Min Mean Max 
        Systolic BP      
       Diastolic BP    
       Heart rate    
 
Interpretation : 
 
Conclusion : 
  
 
 
PATIENT CONSENT FORM 
Study detail:     
 “Prevalence of Masked Hypertension in patients with 
metabolic Syndrome” 
Study centre  :           TERITIARY CARE CENTRE 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well-being or 
any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. 
 
Signature/thumb impression:    
Patients Name and Address:                  place   date 
Signature of investigator :    
Study investigator’s Name :                                  place   date      
�யஒப்�த ப�வம 
 
ஆய் ெசயயபப்ம �ைலப :்  
மறைமுக இரத்த கொதி ப்பு – வளர்சி தை மாற்றம் – 
நோய்த்தாக்கம். 
இடம:           
              ெபா� ம�த�வ �ைற  
                   அர�  கீழபாாகம ம�த�வ கத்ாா ம�த�வமைை 
                  ெசனைை – 10. 
 
பங்ெபபபவாான  ெபயர : 
பங்ெபபபவாான  வய� :                     பங்ெபபபவாான  எண : 
 
ேமேல ்றாபபாி்்� ம�த�வ ஆயவான வாவரஙக் எைா் 
வா�ாகபபிட�.  நான இவவாயவாத �னைாிைசயாக 
பஙேகககாேறன.  எந� காரணத�ாைாேலா எந� சிடசா க்ா்ம 
உிபடாமத நான இவவாயவாத இ�ந� வாலகா ெகா்�தலாம 
எனபம அறாந� ெகாணேடன. 
இந� ஆய் சமபந�மாகேவா,  இை� சாரந� ேம்ம ஆய் 
ேமகெகா்ளமேபா�ம இந� ஆயவாதபங் ெபபம ம�த�வர 
என்ைடய ம�த�வ அறா ைககை� பாரபப�க் என அ்ம�ா 
ே�ைவயாதைல எை அறாந� ெகா்காேறன.  இந� ஆயவான �லம 
காைடா்ம �கவைலேயா, ��ைவேயா பயனப்த�ா ெகா்� 
மபாக மாிேடன. 
இந� ஆயவாத பங் ெகா்� ஒப்ாெகா்காேறன.   இந� 
ஆயைவ ேமகெகா்ளம ம�த�வ அணா ் உணைமமடன 
இ�பேபன எனபம உப�ாய�ா காேறன. 
 
பஙேககபவாான   ைகெயாபபம            ஆயவா�ாான   
ைகெயாபபம 
இடம : 
ே��ா : 
Name  Age Sex  
Weight
Height BMI Clinic SBP DBP Smoker T2DM
Waist 
circum FBS HDL TGL MH‐Yes/No
1 Swaminathan 42 M 72 152 31.2 134 82 No No 106 104 34 201 No
2 Srinivasan 51 M 78 164 29.1 129 86 Yes No 98 132 32 236 yes
3 Meenakshi 46 F 76 159 30.1 136 92 No No 94 132 36 162 yes
4 Sankar 34 M 84 172 28.4 132 88 No No 110 116 41 157 yes
5 Siva Kumar 43 M 72 168 25.5 128 80 yes No 104 136 46 168 No
6 Gowri 41 F 68 158 27.3 133 84 No No 94 101 51 153 No
7 Mary 54 F 63 156 25.9 137 94 No yes 92 134 49 158 yes
8 Rameez 39 M 68 162 25.2 129 86 Yes No 104 99 37 223 yes
9 Dhandapani 42 M 77 171 26.2 135 90 Yes No 106 103 43 214 yes
10 Pachaiyamal 41 F 69 166 25 138 82 No No 90 87 49 198 yes
11 Sasikala 36 F 55 169 19.2 126 80 No No 88 93 56 162 No
12 Saravanan 52 M 66 174 21.71 133 88 Yes No 104 98 40 200 yes
13 Subbiah  45 M 76 172 25.76 137 90 No No 106 110 43 230 yes
14 Sarasu 43 F 66 165 24.2 124 84 No No 90 103 39 152 No
15 Rameela 39 F 56 166 20.3 130 88 No No 88 94 53 150 No
16 Padmavathy 44 F 65 163 24.5 128 82 No No 92 111 49 160 No
17 Govindharaj 55 M 70 157 28.4 139 86 Yes       Yes 108 145 37 236 yes
18 Devi  53 F 64 146 30 133 90 No       No 96 109 51 196 yes
19 Shiek Moideen 44 M 71 169 24.9 137 92 Yes No 106 97 35 225 yes
20 Kaliammal 47 F 58 165 21.3 125 80 No No 90 100 50 157 No
21 Usha 43 F 70 159 27.7 137 86 No No 98 104 48 192 yes
22 Senthil  41 M 67 180 20.7 131 88 No No 102 88 41 160 No
23 Manivel  39 M 87 179 27.2 135 80 Yes No 104 110 38 220 yes
24 Vasantha  41 F 58 163 21.8 130 82 No No 88 92 52 151 No
25 Perumal 49 M 79 178 24.9 135 84 Yes No 92 102 42 187 yes
26 Sumathi 43 F 65 165 23.9 128 82 No No 90 98 51 173 No
27 Dharman 50 M 63 173 21 136 84 Yes No 100 89 35 194 yes
28 Balasubramanian 45 M 72 171 24.6 139 80 No No 106 95 40 204 yes
29 Elumalai 51 M 89 179 27.8 137 85 Yes No 108 101 38 223 yes
30 kanagavalli 46 F 49 160 19.1 126 87 No No 86 118 47 169 No
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31 Rajavel 44 M 66 175 21.6 132 79 No No 104 105 42 164 No
32 Kalvathi 37 F 76 158 30.4 134 80 No No 110 101 49 232 yes
33 Dhanam 56 F 69 161 26.6 137 83 No yes 94 140 46 204 yes
34 Manikkam 54 M 65 172 22 134 79 No No 88 100 35 199 yes
35 Ramula 44 F 59 166 21.4 132 76 No No 86 92 44 185 No
36 chinnaiah 43 M 63 171 21.5 128 72 Yes No 82 86 40 176 No
37 Anjala 52 F 88 159 34.8 134 80 No yes 90 139 52 235 yes
38 Balan 41 M 69 169 24.2 139 88 Yes No 104 100 37 201 yes
39 Pappammal 44 F 71 149 32 137 81 No No 96 98 52 218 yes
40 Saraswathy 43 F 64 157 26 132 79 No No 90 104 46 196 yes
41 Murali 55 M 68 168 24.1 139 80 Yes No 104 87 36 189 yes
42 Kumari 59 F 60 155 25 138 82 No yes 92 129 41 207 yes
43 Edison 45 M 70 170 24.2 136 84 No No 102 100 40 182 yes
44 Farook 52 M 74 172 25 135 90 Yes No 104 86 43 200 yes
45 Kaliyappan 44 M 79 169 27.7 134 84 No No 107 101 38 206 yes
46 Rajeshwari 52 F 65 156 26.7 133 78 No No 92 92 49 192 yes
47 Bharathi 46 F 58 160 22.7 126 80 No No 88 89 53 165 No
48 Banumathi 47 F 62 158 24.8 134 86 No No 90 96 44 215 yes
49 Govindhan 55 M 70 171 23.9 137 90 Yes yes 104 135 45 193 yes
50 Arasammal 48 F 63 166 22.9 135 87 No No 90 101 46 186 yes
51 Ethiraj 42 M 64 175 20.9 129 76 Yes No 102 99 39 169 No
52 Ramesh 39 M 72 169 25.2 124 80 Yes No 102 93 53 158 No
53 Chittibabu 45 M 70 173 23.4 137 88 No No 104 103 36 191 yes
54 Paul Raj 40 M 74 176 23.9 135 86 Yes No 106 97 46 189 yes
55 Vincent Raj 45 M 80 173 26.7 138 90 No No 108 100 39 226 yes
56 Chellathai 47 F 67 163 25.2 134 84 No No 94 89 47 205 yes
57 Ilavarasi 52 F 78 159 30.9 137 89 No No 96 99 43 245 yes
58 Sathyabama 36 F 63 164 23.4 125 78 No No 88 95 51 179 No
59 Chockalingam 45 M 82 174 27.1 133 80 Yes No 110 111 42 203 yes
60 Babu 37 M 77 175 25.1 126 76 No No 104 95 47 163 No
61 Hussain Basar 43 M 69 169 24.2 136 88 Yes No 102 102 35 185 yes
62 Fathima 49 F 68 162 25.9 133 92 No Yes 90 141 47 193 Yes
63 Victor 35 M 71 172 24 124 79 Yes No 102 101 40 175 No
64 Murugan 45 M 69 168 24.4 132 88 No No 104 98 36 200 No
65 Balachandar 43 M 81 176 26.1 137 86 Yes No 104 102 46 197 Yes
